Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Core Insights - Xenon Pharmaceuticals Inc. announced multiple presentations at the American Academy of Neurology Annual Meeting (AAN 2025) focusing on azetukalner for focal onset seizures (FOS) [1][5] - The company highlighted long-term data from the ongoing X-TOLE open-label extension study, showing sustained monthly reduction in seizure frequency and a consistent safety profile for azetukalner [2][5] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for unmet medical needs, particularly in epilepsy and depression [4] - Azetukalner is a novel, highly potent Kv7 potassium channel opener, currently in late-stage clinical development for multiple indications [4] Upcoming Presentations - Three posters will be presented at AAN 2025, including: - Long-term safety and efficacy data from the X-TOLE study [2][5] - Exploratory analysis of efficacy across FOS seizure subtypes [5][6] - Patient survey findings on mental health and comorbidity burdens associated with FOS [5][6] Presentation Details - Poster 9-001 will present long-term safety and efficacy data, with Dr. Jacqueline A. French as the presenter [2][6] - Poster 9-012 will focus on the efficacy of azetukalner in FOS subtypes, presented by Dr. Constanza Luzon Rosenblut [6] - Poster 9-003 will address the mental health burden of epilepsy, presented by Dr. Joanne M. Wagner [6]